Tier 2 — strong

A Randomized Placebo- Controlled Double Blind Clinical Trial of Quercetin in the Prevention and Treatment of Chemotherapy-Induced Oral Mucositis

Mohammad Mahdi Kooshyar, Pegah Mosannen Mozafari, Maryam Amirchaghmaghi, Atessa Pakfetrat, Parisa Karoos, Mahdokht Rashed Mohasel, Hosein Orafai, Amir Abbas Azarian
Journal of clinical and diagnostic research : JCDR 2017 11(3):ZC46

Bibliography

PubMed
PMID 28511508
PubMed Central
PMC5427434
DOI
10.7860/JCDR/2017/23975.9571
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled oncology-support trial
ModelHuman intervention research
Sample20 adults receiving high-dose chemotherapy; 10 per group
InterventionQuercetin 250 mg twice daily versus placebo
Duration4 weeks
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2017, this source examined skin and topical formulations. Design: Randomized double-blind placebo-controlled oncology-support trial. Sample/model: 20 adults receiving high-dose chemotherapy; 10 per group. The exposure or intervention was Quercetin 250 mg twice daily versus placebo. Follow-up or treatment period: 4 weeks.

Mucositis incidence did not differ significantly. Reported mucositis severity was higher in the quercetin group, and healing time did not improve.

Small trial with baseline oral-health concerns. It does not establish prevention or treatment of chemotherapy mucositis.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Skin and Hair: Oral vs Topical Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Mucositis incidence did not differ significantly.
  • Reported mucositis severity was higher in the quercetin group, and healing time did not improve.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Quercetin 250 mg twice daily versus placebo; 4 weeks.

What this study can and cannot tell us

  • Small trial with baseline oral-health concerns. It does not establish prevention or treatment of chemotherapy mucositis.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetin as a Natural Adjunct in Managing Plaque and Gingivitis in Adults: A Randomized Controlled Trial
Ankita Rawal et al. · Cureus · 2026
Tier 2
Efficacy and Safety of Topical Compound Heparin Sodium Allantoin Gel (Main Components: Onion Extract Quercetin) for the Treatment of Rosacea
Zining Xu et al. · Journal of cosmetic dermatology · 2025
Tier 2
Quercetin loaded cosm-nutraceutical electrospun composite nanofibers for acne alleviation: Preparation, characterization and experimental clinical appraisal
Sandra Sherif Amer et al. · International journal of pharmaceutics · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology